Pluvicto turned an unusually clean target into a therapy: prostate cancer expresses PSMA densely and almost uniquely, making it well suited to delivering radiation systemically.
It binds PSMA on tumor cells and delivers beta-emitting lutetium-177 directly to them, largely sparing healthy tissue. Given intravenously every six weeks, it treats adults with PSMA-positive metastatic castration-resistant prostate cancer previously treated with androgen receptor pathway inhibition and taxane-based chemotherapy.
Pluvicto’s launch was constrained by radiopharmaceutical manufacturing and supply capacity rather than demand, and it has since expanded into pre-chemotherapy use. Requiring companion PSMA PET imaging and nuclear medicine infrastructure, it is the reference asset for the radioligand therapy field.
